John Overdeck’s Regeneron Pharmaceuticals REGN Stock Holding History

John Overdeck’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,300	Closed	-$11.6M	–	4031
2021 Q4	$11.6M	Sell	18,300 -3,600	-16%	-$2.21M	0.02%	710
2021 Q3	$13.3M	Sell	21,900 -5,400	-20%	-$3.35M	0.03%	638
2021 Q2	$15.2M	Buy	27,300 +7,900	+41%	+$4M	0.03%	604
2021 Q1	$9.18M	Sell	19,400 -3,300	-15%	-$1.61M	0.02%	735
2020 Q4	$11M	Buy	22,700 +14,300	+170%	+$7.72M	0.03%	560
2020 Q3	$4.7M	Buy	+8,400	New	+$5.09M	0.02%	819
2020 Q2	–	Sell	-10,500	Closed	-$5.13M	–	3430
2020 Q1	$5.13M	Sell	10,500 -8,100	-44%	-$3.34M	0.04%	489
2019 Q4	$6.98M	Buy	18,600 +2,300	+14%	+$774K	0.02%	776
2019 Q3	$4.52M	Buy	16,300 +1,600	+11%	+$473K	0.02%	918
2019 Q2	$4.6M	Buy	14,700 +2,700	+23%	+$899K	0.02%	942
2019 Q1	$4.93M	Buy	12,000 +9,000	+300%	+$3.71M	0.02%	969
2018 Q4	$1.12M	Buy	3,000 +2,000	+200%	+$732K	﹤0.01%	1584
2018 Q3	$404K	Sell	1,000 -22,700	-96%	-$8.64M	﹤0.01%	2595
2018 Q2	$8.18M	Sell	23,700 -1,300	-5%	-$407K	0.02%	751
2018 Q1	$8.61M	Buy	25,000 +22,300	+826%	+$7.76M	0.03%	662
2017 Q4	$1.01M	Sell	2,700 -5,800	-68%	-$2.35M	﹤0.01%	1970
2017 Q3	$3.8M	Buy	+8,500	New	+$4.04M	0.01%	938
2017 Q2	–	Sell	-4,000	Closed	-$1.55M	–	3225
2017 Q1	$1.55M	Buy	4,000 +2,000	+100%	+$741K	0.01%	1610
2016 Q4	$734K	Sell	2,000 -13,000	-87%	-$4.94M	﹤0.01%	2233
2016 Q3	$6.03M	Buy	15,000 +12,000	+400%	+$4.81M	0.02%	782
2016 Q2	$1.05M	Buy	+3,000	New	+$1.16M	﹤0.01%	1696
2016 Q1	–	Sell	-5,000	Closed	-$2.71M	–	3074
2015 Q4	$2.71M	Buy	5,000 +2,000	+67%	+$1.08M	0.01%	930
2015 Q3	$1.4M	Buy	+3,000	New	+$1.61M	0.01%	1012
2015 Q2	–	Sell	-1,000	Closed	-$451K	–	3046
2015 Q1	$451K	Buy	+1,000	New	+$424K	﹤0.01%	2031

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

John Overdeck's REGN Position: Q2 2026 in Review

John Overdeck reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, selling an estimated $106M and leaving 656,124 shares worth $409M. The position accounts for 0.3% of the portfolio, ranked #59.

John Overdeck first reported a position in REGN in Q2 2013 and has held it in 37 quarters since. The position peaked at $628M in Q1 2026. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

John Overdeck held 656,124 shares of Regeneron Pharmaceuticals worth $409M as of Q2 2026.
John Overdeck sold 156,112 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $106M.
Regeneron Pharmaceuticals made up 0.3% of John Overdeck's portfolio in Q2 2026, its #59 holding.
John Overdeck first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
John Overdeck's Regeneron Pharmaceuticals position peaked at $628M in Q1 2026.
1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.